The tyrosine kinase CSK associates with FLT3 and c-Kit receptors and regulates downstream signaling.
Introduction
The protein tyrosine kinase is one of the largest groups of protein kinases in mammalian genome encoding by more than 90 different genes [1, 2] . This group is further divided into 20 families of receptor tyrosine kinases (RTKs) and 10 families of non-receptor tyrosine kinases (NRTKs). The type III receptor tyrosine kinase (also known as PDGFR family) is a family of RTKs consisting of five RTKs including CSF1R, FLT3, c-Kit, PDGFR and PDGFR. Members of this family of proteins play important roles in a number of physiological conditions and many of them are frequently mutated in variety of cancers [3] [4] [5] [6] . While RTKs need ligand binding to the extracellular domains for dimerization and activation, oncogenic mutations allows RTKs to escape from the ligand dependency for activation [4] .
Receptor activation triggers a plethora of downstream signaling pathways which are tightly regulated by a number of different interacting proteins. For example, association of Grb10 or SLAP with FLT3 enhances downstream signaling while SOCS2, SOCS6 or LNK negatively regulates signaling of the same receptor [7] [8] [9] [10] [11] . The c-Kit signaling has also been reported to be regulated by various interacting proteins such as Grb2, SHP2 , Cbl, Crk etc. (for review see [3] ). A number of interacting proteins modulate receptor signaling by altering its stability while others help the receptor to transduce information by recruiting signaling proteins.
The Src family tyrosine kinases (SFKs) are a major group of non-receptor tyrosine kinases abundantly expressed in variety of cells. This family is comprised of eight members including Src, Yes, Fyn, Fgr, Lyn, Hck, Lck and Blk. The C-terminal Src kinase (CSK; also known as C-terminal Src kinase) and CSK homologous kinase (CHK) are well-known negative regulators of SFKs which phosphorylate SFKs at the C-terminal tyrosine residue corresponding to Y530 in the human sequence of Src. This residue along with CSK recognition sequence is highly conserved within the SFKs [12] .
Phosphorylation of the C-terminal tyrosine residue allows SFKs to fold in an inactive conformation.
Thus, loss of CSK function results in an aberrant activation of SFKs as well as survival pathways. In this report we show that CSK associates with various type III receptor tyrosine kinases and differentially regulates receptor signaling.
Materials and Methods

Plasmids
The pcDNA3-FLT3-WT, pcDNA3-FLT3-ITD, pcDNA3-c-Kit-WT, pcDNA3-c-Kit-D816V, pMSCV-c-Kit-WT, pMSCV-c-Kit-D816V and pcDNA3-PDGFRβ plasmids were described elsewhere [13] [14] [15] . The pMSCV-FLT3-WT and pMSCV-FLT3-ITD plasmids were a kind gift from Dr. D. Gary Gilliland. We generated a modified pcDNA3 vector (pcFLAG) by inserting double strand oligo containing M-BamHI-XhoI-FLAG-Stop. We used pcFLAG vector to sub-clone wild-type human CSK using BamHI and XhoI cloning sites. The CSK-R107E mutant was generated by site directed mutagenesis using the QuikChange mutagenesis XL kit (Stratagene, La Jolla, CA). The CSK-ΔSH3 (73 to 450 amino acids) and CSK-SH3-SH2 (2 to 190 amino acids) mutants were generated by sub-cloning respective parts of human CSK in pcFLAG vector.
Antibodies
Rabbit polyclonal anti-FLT3, anti-c-Kit, anti-PDGFRβ and anti-Erk antibodies were described previously [13] [14] [15] . Mouse anti-FLAG and anti-β-Actin antibodies were purchased from Sigma. Phycoerythrin (PE)-conjugated anti-FLT3 and anti-c-Kit antibodies were from BD Biosciences. Rabbit polyclonal anti-phospho-Gab2, anti-phospho-SHP2 and Alexa Fluor 647 conjugated anti-FLAG antibodies were from Cell signaling. Rabbit polyclonal anti-CSK, antiphospho-Erk1/2, anti-SHP2 and goat polyclonal anti-Akt antibodies were from Santa Cruz Biotechnology. Mouse anti-mono-ubiquitin antibody was form Covance Research Products. General phosphotyrosine antibody 4G10 was from Millipore. Rabbit polyclonal anti-Akt antibody was form Epitomics. Mouse monoclonal anti-phospho-p38 and anti-p38 antibodies, and rabbit anti-SHC antibody were from BD Transduction Laboratories.
Chemical reagents, ligands and siRNAs
The transfection reagents jetPEI and Lipofectamine 2000 were from Polyplus-transfection SA and Invitrogen respectively. Cycloheximide and MG132 were from Sigma. Chloroquine diphosphate was from Sigma. FLT3 ligand (FL), stem cell factor (SCF), and PDGF-BB were purchased from Prospec Tany.
Cell culture
The COS-1 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Ba/F3 cells were cultured in RPMI 1640 medium supplemented with 10% heat inactivated FBS and 10 ng/ml recombinant murine interleukin-3 (IL-3).
Since IL3-withdrawal interferes functional redundancy of oncogenic FLT3 and c-Kit signaling [16] , we used IL-3 containing medium for the culture of all transfected Ba/F3 cells.
Transient transfection
The JetPEI transfection reagent (Polyplus Transfection) was used for transient transfections.
Cells were seeded in the evening for next morning transfections. For co-transfections, 5 µg of total plasmids (2 µg receptor plasmid, 3 µg CSK plasmid) and 15 µl of JetPEI were used. Transfection was carried out in a 10 cm petri-dish with 5 ml of complete medium. Six hours after transfection cells washed with PBS for three times and cultured in serum free medium for 18 hours before stimulation and/or lysis.
Retroviral transduction
Retroviral transfection procedure was described previously [8, 9] . In brief, packaging EcoPack cells were transfected with respective plasmids using Lipofectamine 2000 (Life Technologies) as per the manufacturers' protocol. Six hours after transfection medium was replaced with fresh complete growth medium. Cells were then grown for 48 hours to produce viral particles.
Then Ba/F3 cells were cultured in medium containing viral particles for 24 hours and were grown for an additional 48 hours in complete Ba/F3 medium before starting puromycin selection.
Electroporation of siRNA
For siRNA transfection to Ba/F3 cells, we used 4D-Nucleofector system from Lonza. Cells were washed with PBS before transfection. Five million cells were used to transfect 6 µg of siRNA in 100 µl of SG solution (Lonza) using CM150 program.
Immunoprecipitation, SDS-PAGE and Western blotting
Ba/F3 cells were kept in IL-3 and serum-free medium for 4 hours before stimulation. After stimulation cells were washed with ice-cold PBS. Cells were then lysed in 1% Triton X100 on ice.
Lysates were processed for immunoprecipitation, SDS-PAGE and Western blotting [8] .
Subcellular localization:
Cells transfected with respective CSK and FLT3/c-Kit plasmids were fixed using 4% paraformaldehyde. Cells were then permeabilized with 0.5% Triton X100 and blocked with 5% goat serum. Cells were stained with fluorophore-conjugated anti-FLAG and anti-FLT3/anti-c-KIT antibodies. Nuclei were stained with DAPI and subcellular localization was visualized with a Carl Zeiss LSM 710 Laser Scanning Microscope.
Receptor Ubiquitination
Cells were serum starved for 4 hours and then incubated with MG132 and chloroquine diphosphate for 30 minutes. Cells were then stimulated with FL or SCF for the indicated period of time in presence of MG132 and chloroquine diphosphate and processed for lysis. Cell lysates were immunoprecipitated with an anti-FLT3 or anti-c-Kit antibody followed by Western blotting analysis.
Cell proliferation
Transfected Ba/F3 cells were washed three times with PBS to remove IL-3 and seeded in 96-well plates (10,000 cells/well). Cells were then incubated with or without 100 ng/ml FL or SCF for 46 hours. Then10 μl of PrestoBlue ((Molecular Probes) was added to each well, followed by 2 h of incubation. Absorbance at 570 nm and 600 nm was measured using a 96-well plate reader and cell viability was calculated according to the manufacturer's protocol.
Cell survival
The annexin V/7-aminoactinomycin D kit (Pharmingen) was used to measure cell survival. Doublenegative (annexin V/7-aminoactinomycin D) cells were counted using BD FACSArray (BD Biosciences) for cell survival.
Results
CSK associates with FLT3 and c-Kit in a phosphorylation dependent manner
Besides association with SFKs, CSK interacts with several receptors including insulin receptor (IR), insulin-like growth factor-I receptor (IGF-IR) [17] and T cell antigen receptor (TCR) zeta [18] . Phosphorylation on receptors' tyrosine residues was essential for interaction. Type III receptors also become phosphorylated on multiple tyrosine residues upon ligand stimulation. Thus we tested whether type III receptor tyrosine kinases also interact with CSK. We used transient transfection to detect interactions. COS-1 cells were transfected with FLAG-tagged CSK and FLT3, c-Kit or PDGFRβ constructs. We observed that CSK associates with FLT3 ( Fig. 1A ), c-Kit ( Fig. 1B) and PDGFRβ (Fig. 1C ). This association was dependent on ligand stimulation and oncogenic mutants of FLT3 (FLT3-ITD) and c-Kit (c-Kit-D816V) displayed constitutive association with CSK ( Fig. 1A-B ). These data indicate that CSK interacts with receptor tyrosine kinases FLT3, c-Kit and PDGFRβ, and that receptor phosphorylation is required for association. Although, we demonstrated interaction between CSK and multiple type III RTKs by overexpressing both proteins, we failed to detect an endogenous interactions probably due to the poor specificity of the antibodies used.
CSK-SH2 domain is sufficient for the interaction with FLT3 and c-Kit
The IGF-IR and IR interact with CSK through the CSK-SH2 domain [17] . Since we observed that receptor phosphorylation is required for association of CSK with FLT3 and c-Kit we hypothesized that CSK associates with FLT3 and c-Kit through the CSK SH2 domain. To verify our hypothesis we generated multiple CSK mutants (Fig. 1D ). The CSK-R107E mutant lacks a critical arginine residue in the phosphotyrosine binding pocket of the SH2 domain which is replaced by 8 negatively charged glutamic acid. This mutation abrogates the ability to the SH2 domain to interact with phosphotyrosine residues. Indeed, we observed that neither FLT3 ( Fig. 1E, 3rd panel) nor c-Kit ( Fig. 1F, 3rd panel) was able to associate with CSK-R107E mutant indicating that a functional CSK-SH2 domain is required for interaction. Conversely, either the SH3 domain deletion mutant (CSK-ΔSH3) or a kinase domain deletion mutant (CSK-SH3-SH2) associated fairly with both FLT3 (Fig.   1E ) and c-Kit (Fig. 1F ). Thus we assert that CSK interacts with receptor tyrosine kinases through its SH2 domain and that the SH3 domain is not required for interaction.
CSK is recruited to the cell membrane in response to ligand stimulation
A previous study showed that CHK translocates from the cytosol to the membrane vicinity upon heregulin stimulation and associates with the ERBB2 receptor [19] . CSK displays considerable structural homology as well as functional similarity to CHK. Thus it is of relevance to check whether CSK also localizes to the cytoplasmic side of the cell membrane in response to FL and SCF. We stained CSK-FLAG and FLT3-WT or c-Kit-WT transfected cells with fluorophore-conjugated anti-FLAG and anti-FLT3 or anti-c-Kit antibodies. We observed that under basal conditions CSK is predominantly localized within the cytosolic compartment, but upon ligand stimulation it is recruited to the plasma membrane ( Fig. 2A and 2B ). Similar localization patterns were displayed by the CSK-ΔSH3 ( Fig. 2C and 2D ) and CSK-SH3-SH2 ( Fig. 2E and 2F ) mutants. On the contrary, the nonfunctional SH2-domain mutant (CSK-R107E) did not show a membrane translocation ( Fig. 2G and   2H ). Furthermore, colocalization in between receptors and CSK was significantly increased in all functional SH2 domain containing CSK mutants ( Fig. 2I and 2J) . These results suggest that a functional SH2 domain is required for the interaction with the receptor and thus for the localization of CSK to the inner side of the plasma membrane.
CSK depletion did not alter neither receptor ubiquitination nor phosphorylation
Several receptor interacting proteins alter receptor stability and/or phosphorylation. For instance, SOCS6 and SLAP accelerate receptor degradation by increasing ubiquitination without interfering with phosphorylation [8, 10] , while LNK associates with FLT3 and decreases FLT3 phosphorylation [7] . To test whether CSK disrupts receptor stability or phosphorylation, we generated stably transfected Ba/F3 cells by transfecting either FLT3 or c-Kit. Ba/F3 cells express a decent level of endogenous CSK. To study the effects of CSK on FLT3 and c-Kit receptors, we attempted to silence CSK by means of CSK specific siRNA achieving up to 76% of knockdown of endogenous CSK (Fig. 3A) . CSK depletion did not significantly affect neither FLT3 ubiquitination nor phosphorylation ( Fig. 3B and 3C) . Similarly to FLT3, ubiquitination or phosphorylation of c-Kit was also not altered by CSK siRNA (Fig. 3D and 3E ).
CSK negatively regulates ligand-induced Akt phosphorylation
CSK regulates integrin-mediated signaling through Akt activation [20] and overexpression of CHK potentiates Akt phosphorylation in breast cancer MCF-7 cell line [21] . Furthermore, CSK overexpression in PC12 cells leads to increased Akt phosphorylation in response to nerve growth factor [22] . These observations suggest that CSK and its homologous kinase differentially regulate Akt activation in different biological contexts, although both proteins exhibit similar function in SFKs regulation. Thus we tested whether CSK plays a role in FL-or SCF-mediated Akt activation. Ba/F3-FLT3-WT or Ba/F3-c-Kit-WT cells were transfected with control siRNA or CSK siRNA. Two days after transfections cells were serum-starved for four hours before ligand stimulation. We observed that CSK depletion led to an increase in Akt activation in both Ba/F3-FLT3-WT ( Fig. 4A) and Ba/F3-c-Kit-WT ( Fig. 4B ) cells suggesting that CSK acts as a negative regulator of Akt signaling downstream to type III receptor tyrosine kinases. In addition, a selective CSK inhibitor (ASN2324598) [23, 24] also augmented Akt phosphorylation in response to both FL (Fig. 4C) or SCF (Fig. 4D ) stimulation indicating that functional CSK is required to maintain basal Akt phosphorylation.
CSK differentially regulates FL-and SCF-induced Erk1/2 phosphorylation
Type III receptor tyrosine kinases transduce mitogenic signaling through activation of the Erk mitogen-activated protein kinase [3] [4] [5] . Overexpression of CSK decreases Erk1/2 phosphorylation in response to different stimuli [20, 22] . We observed that while CSK knockdown enhanced Erk1/2 phosphorylation in response to FL stimulation (Fig. 5A) , it decreased Erk1/2 phosphorylation in response to SCF (Fig. 5B) . The ASN2324598-mediated CSK inhibition led to a prolonged Erk1/2 activation in response to both FL ( Fig. 5C ) and SCF (Fig. 5D ). On the whole, these results indicate that CSK differentially regulates MAPK signaling downstream of FLT3 and c-Kit receptors and that intact CSK is required for c-Kit-mediated Erk1/2 signaling.
CSK depletion has no significant effect on p38 activation
Since both FL and SCF can activate p38, we then tested whether CSK also controls ligandstimulated p38 phosphorylation. CSK depletion slightly decreased FL-stimulated p38 phosphorylation at the 2 minute time point but slightly increased at the 5 minute time point (Fig. 6A ). Similar to FL, SCF induced p38 activation was slightly attenuated in CSK knockdown cells at the 2 minute time point ( Fig. 6B ). Although knockdown of CSK led to a slight deregulation of p38 phosphorylation induced by either receptor, differences were not statistically significant.
CSK depletion increases SHC, Gab2 and SHP2 tyrosine phosphorylation
Activation of Akt and Erk1/2 by receptor tyrosine kinases FLT3 and c-Kit is mediated through activation of various signaling proteins such as SHP2, SHC and Gab2 [3, 4] . Therefore we tested which intermediate regulators are involved in transducing signals from FLT3 and c-Kit receptors through CSK. Ba/F3-FLT3-WT and Ba/F3-c-Kit-WT cells were transfected with control and CSK siRNA. Two days after transfection cells were serum-starved for four hours followed by two minutes and five minutes ligand stimulation. We observed that phosphorylation on tyrosine residues of SHC was increased in CSK siRNA transfected cells in response to both FL (Fig. 7A) and SCF (Fig.   7B ). Using phospho-specific antibodies against phosphotyrosine residues in Gab2 we showed that both FL (Fig. 7C) and SCF (Fig. 7D ) stimulation enhanced Gab2 phosphorylation in cells where CSK expression had been knocked down. Similarly to SHC and Gab2, we also observed an increase in SHP2 phosphorylation following knockdown of CSK in Ba/F3-FLT3-WT ( Fig. 7E) and Ba/F3-c-Kit-WT ( Fig. 7F ) cells upon respective ligand stimulation.
CSK depletion increases oncogenic FLT3-and c-Kit-mediated cell proliferation but not cell survival
Since we observed that CSK differentially regulates Akt and Erk1/2 signaling in response to the FL and SCF stimulation, we investigated whether CSK depletion resulted in differential biological outcomes. We tested cell proliferation and survival using constitutively active mutants of FLT3 and c-Kit which are known to induce IL-3-independent Ba/F3 cell survival [16] . We observed that CSK depletion resulted in an increased proliferation of Ba/F3-FLT3-ITD ( Fig. 8A) and Ba/F3-c-Kit-D816V cells (Fig. 8B) , while cell survival remained unchanged ( Fig. 8C and 8D ).
Discussion
The C-terminal Src kinase (CSK) contributes to regulation of SFKs activity. Thus, loss of CSK function mediates aberrant SFK signaling leading to abnormal cell growth. Apart from its catalytic activity CSK is known to interact with variety of signaling proteins. CSK associates with TCR complex through CSK-SH2 domain and this interaction brings CSK closer to SFKs resulting in negative regulation of TCR signaling [18] . In this study, we demonstrate that CSK associates with multiple type III receptor tyrosine kinases. Moreover, we showed that a functional CSK SH2 domain is necessary for interactions to the activated receptors. Furthermore, our results indicate that ligand activation triggers CSK membrane localization and that CSK regulates receptor downstream signaling eventually leading to receptors-mediated cell proliferation.
Both CSK and CHK deficient mice have been generated. Although CHK deficient mice survived and were apparently healthy [25] , CSK deficient mice died due to defects in the neural tissues [26, 27] suggesting that CSK plays additional roles in embryogenesis other than regulation of SFKs. Differential subcellular localization in response to different physiological stimulant might regulate downstream signaling differentially. Many kinases display differential localization patterns and thereby differentially regulate downstream signaling [28] [29] [30] [31] . CSK probably also elicit different signaling whether it is cytosolic or membrane-localized. While cytosolic CSK interacts with adapters or scaffold proteins [12] , membrane localized CSK associates with receptors and transduces or blocks receptor signaling.
CSK is predominantly present in cytosol due to lack of a transmembrane domain or fatty-acyl modifications, but its substrate SFKs are mainly anchored inner surface of the cell membrane.
Association of CSK with ligand-stimulated receptors brings CSK in close proximity to the cell membrane where it phosphorylates SFKs [12] . Since, both FLT3 and c-Kit transduce signal through SFKs [4] , CSK association with the receptors might have negative impact on receptor downstream signaling. Elevated SHC phosphorylation in CSK depleted cells further supports this hypothesis.
SFKs induce tyrosine phosphorylation of several signaling proteins including Gab2 and SHP2
resulting in activation of downstream serine/threonine kinases Akt and Erk1/2 [4] . Our data also suggests that loss of CSK function contributes to increased Gab2 and SHP2 tyrosine phosphorylation as well as to increased Akt serine phosphorylation. Since activation of the Akt pathway facilitates cell survival and proliferation through transcriptional activation of cell cycle activators and phosphorylation-dependent inactivation of cell cycle repressors [4, 32] , it is anticipated that depletion of CSK will further accelerate oncogenic receptor-mediated cell proliferation.
The observation that CSK depletion or inhibition elevated FL-induced Erk1/2 phosphorylation could also be explained by the fact that loss of CSK function reduces control of SFKs activation. However, while CSK inhibition potentiated SCF-induced Erk1/2 phosphorylation which is in line with the FLT3 downstream signaling, siRNA-mediated CSK depletion decreased SCFmediated phosphorylation of same proteins. This observation cannot be explained by an influence on SFKs regulation and it is of interest how CSK association to the c-Kit induces prolonged Erk1/2 phosphorylation. One possible explanation could be adaptor activity. The presence of both SH3 and SH2 domains helps many proteins to link multiple signaling proteins [33] . Thus, CSK might link c-Kit with other signaling proteins resulting in activation of Erk1/2 which is independent of the regulations of SFKs.
Conclusions
In this study we demonstrate that CSK associates with multiple type III receptor tyrosine kinases including FLT3 and c-Kit. While this association is mediated through CSK SH2 domain and tyrosine phosphorylated receptors, SH3 domain is not required for the interaction. Association of CSK with receptors increases the membrane localization of CSK resulting in extended SFKs regulation, which further controls of downstream PI3K-Akt pathway as well as cell proliferation. Although 
